{
    "2021-09-10": [
        [
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)股东贝成投资解除质押150万股",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "股东",
                        "贝成投资",
                        "解除质押",
                        "150万股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：公司已提交埃克替尼术后辅助治疗适应症和恩沙替尼二线治疗适应症的国谈申请，并已通过公示",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "埃克替尼",
                        "术后辅助治疗",
                        "恩沙替尼",
                        "二线治疗",
                        "国谈申请",
                        "通过公示"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：BPI-9016M是一种以c-Met和Axl为靶点的小分子激酶抑制剂，为口服制剂",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "BPI-9016M",
                        "c-Met",
                        "Axl",
                        "小分子激酶抑制剂",
                        "口服制剂"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业：风物长宜放眼量",
                "features": {
                    "keywords": [
                        "医药生物行业",
                        "风物长宜放眼量"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}